高级检索

黄芪白术汤辅助动脉灌注疗法治疗晚期卵巢癌患者的疗效评价

Effect of Huangqi Baizhu Decoction combined with arterial perfusion therapy for patients with advanced ovarian cancer

    摘要
  • 摘要:
    目的 探讨黄芪白术汤辅助动脉灌注疗法对晚期卵巢癌患者临床疗效、卵巢血流参数以及免疫功能的影响。
    方法 选取天津市肿瘤医院秦皇岛医院2021年1月—2023年1月收治的168例晚期卵巢癌患者为研究对象, 随机分为对照组(单纯动脉灌注疗法)和观察组(动脉灌注疗法联合黄芪白术汤治疗)，每组84例。治疗2个周期后，比较2组临床疗效、卵巢血流参数收缩期峰值流速(PSV)、舒张末期流速(EDV)、阻力指数(RI)、免疫功能指标T淋巴细胞亚群、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)以及不良反应发生率。
    结果 观察组总缓解率为66.67%(56/84), 高于对照组的42.86%(36/84), 差异有统计学意义(χ2=9.612, P=0.002)。治疗2个周期后，观察组PSV、EDV、CD3+、CD4+、CD4+/CD8+、IgG、IgA、IgM高于对照组, RI、CD8+、C反应蛋白(CRP)低于对照组, 差异均有统计学意义(P < 0.05)。观察组不良反应总发生率为61.90%(52/84), 低于对照组的92.86%(78/84), 差异有统计学意义(P < 0.05)。随访1年，观察组失访2例，对照组失访3例，随访率分别为97.62%、96.43%。观察组总生存期为(10.82±1.56)个月，长于对照组的(8.35±1.32)个月，差异有统计学意义(Log-rank χ2=18.256, P < 0.001); 观察组无进展生存期为(8.64±1.21)个月，长于对照组的(6.18±1.05)个月，差异有统计学意义(Log-rank χ2=21.364, P < 0.001)。
    结论 黄芪白术汤辅助动脉灌注疗法可提高晚期卵巢癌患者临床治疗有效率, 改善卵巢血流灌注，增强机体细胞免疫与体液免疫功能，减轻化疗相关胃肠道反应，并降低骨髓抑制发生率。

     

    Abstract:
    Objective To investigate the effects of Huangqi Baizhu Decoction combined with arterial perfusion therapy on clinical efficacy, ovarian blood flow parameters, and immune function in patients with advanced ovarian cancer.
    Methods A total of 168 patients with advanced ovarian cancer in the Qinhuangdao Hospital of Tianjin Cancer Hospital from January 2021 to January 2023 were selected as the study subjects, and they were randomly divided into control group (arterial perfusion therapy alone) and observation group (arterial perfusion therapy combined with Huangqi Baizhu Decoction), with 84 cases in each group. After two treatment cycles, the clinical efficacy, ovarian blood flow parameters peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistance index (RI), immune function indicators T lymphocyte subsets, immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M(IgM), and the incidence of adverse reactions were compared between the two groups.
    Results The overall response rate in the observation group was 66.67% (56/84), which was significantly higher than 42.86% (36/84) in the control group (χ2=9.612, P=0.002). After two treatment cycles, the PSV, EDV, CD3+, CD4+, CD4+/CD8+, IgG, IgA, and IgM levels in the observation group were significantly higher than those in the control group, while the RI, CD8+, and C-reactive protein (CRP) levels were significantly lower than those in the control group (all P < 0.05). The overall incidence of adverse reactions in the observation group was 61.90% (52/84), which was significantly lower than 92.86%(78/84) in the control group (P < 0.05). During the one-year follow-up, 2 patients in the observation group and 3 patients in the control group were lost to follow-up, with follow-up rates of 97.62% and 96.43%, respectively. The overall survival in the observation group was (10.82±1.56) months, which was significantly longer than (8.35±1.32) months in the control group (Log-rank χ2=18.256, P < 0.001). The progression-free survival in the observation group was (8.64±1.21) months, which was significantly longer than (6.18±1.05) months in the control group (Log-rank χ2=21.364, P < 0.001).
    Conclusion Huangqi Baizhu Decoction combined with arterial perfusion therapy can significantly improve the clinical efficacy, enhance ovarian blood perfusion, strengthen cellular and humoral immune functions, and reduce the incidence of chemotherapy-related gastrointestinal reactions and myelosuppression in patients with advanced ovarian cancer.

     

    • HTML全文
    • 参考文献(23)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回